SanoLibio in Use

24.05.2022 – SanoLibio announces the commencement of a clinical trial conducted by its partner company Premise Biosystems Co., Ltd. (Thailand) in collaboration with Rama Thibodi Hospital in Bangkok for the validation of a novel cell-based liquid biopsy platform using our customer pilot WalderbachIIa.

The liquid biopsy platform relies on ultra-high efficient removal of cellular noise as to detect abnormality in the so called circulating rare cell population.

The hypothesis of the study is to positively correlate specific circulating rare cell markers with tumor burden and systemic disease in pre- and post-surgery particularly early-stage breast cancer patients.